For the quarter ending 2025-06-30, YMAB made $19,525K in revenue. -$5,252K in net income. Net profit margin of -26.90%.
| Income Statement | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 19,525 | 20,904 | 21,963 | 18,461 |
| Cost of goods sold | 2,662 | 3,001 | 5,947 | 2,248 |
| Gross profit | 16,863 | 17,903 | 18,171 | - |
| Research and development | 11,104 | 11,359 | 12,741 | 11,168 |
| Selling, general, and administrative | 11,313 | 13,087 | 6,873 | 13,613 |
| License royalties | 50 | - | 63 | - |
| Total operating costs and expenses | 22,467 | 24,446 | 19,676 | 27,029 |
| Loss from operations | -5,604 | -6,543 | -6,422 | -8,568 |
| Interest and other income | 2,372 | 1,352 | -583 | 1,916 |
| Loss before income taxes | -3,232 | -5,191 | -7,005 | -6,652 |
| Provision for income taxes | 7 | 5 | -296 | 346 |
| Net loss | -3,239 | -5,196 | -6,709 | -6,998 |
| Foreign currency translation | -2,013 | -863 | 1,350 | -1,083 |
| Comprehensive loss | -5,252 | -6,059 | -5,360 | -8,081 |
| Earnings per share, basic | -0.07 | -0.12 | -0.15 | -0.16 |
| Earnings per share, diluted | -0.07 | -0.12 | -0.15 | -0.16 |
| Weighted average number of shares outstanding, basic | 45,318,028 | 45,104,476 | -22,160,168.5 | 44,626,943 |
| Weighted average number of shares outstanding, diluted | 45,318,028 | 45,104,476 | -22,160,168.5 | 44,626,943 |
Y-mAbs Therapeutics, Inc. (YMAB)
Y-mAbs Therapeutics, Inc. (YMAB)